GlobeNewswire Inc | Jun 15, 2021 04:01PM EDT

June 15, 2021

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Companys newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D., and Senior Vice President and Chief Regulatory Officer, Chi Li, Ph.D. In connection with the appointments, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to each of Drs. Shearman and Li as inducements material to their entering into employment withEditas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). Drs. Shearmans and Lis stock options provide for the purchase of up to 52,718 shares and 44,202 shares, respectively, of Editas Medicine common stock at a price of$38.53per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq onthe date of grant, and vest over four years, with 25 percent of the shares vesting on the first anniversary of each individuals employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to their continued service relationship with Editas Medicine through the applicable vesting dates.Drs. Shearmans and Lis restricted stock unit awards are for 32,701 shares and 14,144 shares, respectively, of Editas Medicine common stock and vest as to 25 percent of the shares on each one-year anniversary of their employment start date until the fourth anniversary of their employment start date, subject to their continued service to Editas Medicine through the applicable vesting dates.

AboutEditas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:MediaCristi Barnett(617) 401-0113cristi.barnett@editasmed.com

InvestorsRon Moldaver(617) 401-9052ir@editasmed.com